Skip to content

A comparison of combined ultrasound with Platelet-rich plasma for the treatment of knee osteoarthritis

A comparison of combined ultrasound with Platelet-rich plasma for the treatment of knee osteoarthritis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065119
Enrollment
Unknown
Registered
2022-10-28
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

control group:PRP
experimental group A:PRP+LIFU
experimental group B:PRP+TENS
experimental group C:PRP+(LIFU+TENS)

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of osteoarthritis using the American College of Rheumatology criteria; 2. Radiological grading of Grade I–III osteoarthritis (OA) of the knee using the Kellgren and Lawrence system.

Exclusion criteria

Exclusion criteria: 1. KELLGREN-LAWRENCE imaging grades IV; 2. Previous internal and external fixation brackets after joint surgery; 3. The patients with local skin ulceration,infection or local skin sensory disturbance; 4. The patients have used anti-inflammatory drugs in the past two weeks and non-steroidal anti-inflammatory drugs in the past two days; 5. The patients combined with language listening and speaking impairment or unable to cooperate with the doctor's treatment; 6. The patients with a pacemaker; 7. The patients with blood system diseases.

Design outcomes

Primary

MeasureTime frame
VAS;

Secondary

MeasureTime frame
International Knee Documentation Committee;Western Ontario and McMaster Universities;

Countries

China

Contacts

Public ContactHongchen He

West China Hospital of Sichuan University

66362265@qq.com+86 189 8060 2262

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026